Basic Information
| LncRNA/CircRNA Name | LINC00525 |
| Synonyms | NA |
| Region | GRCh38_7:47761476-47766772 |
| Ensemble | ENSG00000146666 |
| Refseq | NR_038407 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Oxaliplatin | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | Colorectal Cancer |
| ICD-0-3 | C19.9 |
| Methods | qPCR, Western blot, Luciferase reporter assay |
| Sample | human CRC cell lines including Caco2, SW480, SW620, HCT116 and HT29 and normal human intestinal epithelial cell line (HIEC), CRC specimens and normal intestine tissue |
| Expression Pattern | up-regulated |
| Function Description | High expressions of LINC00525 were associated with poor prognosis of CRC patients. LINC00525 knockdown decreased stemness properties and increased sensitivities to oxaliplatin. MiR-507 was a direct target of LINC00525 and overexpression of miR-507 significantly decreased abilities of tumorsphere formation and cell growth. Overexpression of miR-507 resulted in a decrease of expression of cancer stem cell markers and the increase of apoptosis rates. MiR-507 regulated the expression of ELK3. In addition, LINC00525 knockdown decreased the expression of ELK3. Restoration of ELK3 expression abrogated the effects of LINC00525 knockdown. LINC00525 could be served as prognostic marker of CRC. |
| Pubmed ID | 31242722 |
| Year | 2019 |
| Title | Long Non-Coding RNA LINC00525 Promotes the Stemness and Chemoresistance of Colorectal Cancer by Targeting miR-507/ELK3 Axis |
External Links
| Links for LINC00525 | GenBank HGNC NONCODE |
| Links for Colorectal Cancer | OMIM COSMIC |